

कार्यवाही स. : 277/145/2026/F

Proceeding No: 277/145/2026/F

Minutes of the 277th (overall) and 145th meeting of the Authority under DPCO, 2013 held on 30.04.2026 at 12:30 PM.

The 277th meeting of the Authority (overall), which is the 145th meeting under the DPCO, 2013 was held on 30th April, 2026 at 12:30 PM under the Chairmanship of Shri P. Krishnamurthy, Chairman, NPPA. The following Authority members were present during the meeting:

- (i) Ms. Sai Ahlladini Panda, Member Secretary, NPPA
- (ii) Dr. Rose Mary K. Abraham, Economic Advisor, Department of Economic Affairs
- (iii) Shri Vijay Kumar, Adviser (Cost), O/o Chief Adviser (Cost), Department of Expenditure

Shri Ranga Chandrashekar, Joint Drug Controller, CDSCO, Ministry of Health & Family Welfare.

The following officers of NPPA attended the meeting and assisted the Authority in its deliberations:

- (i) Shri Sanjay Kumar, Adviser (Cost)
- (ii) Ms. Priyanka Sachdeva, Joint Director (Pricing)
- (iii) Ms. Yuvika Panwar, Deputy Director (Pricing) – Additional Charge
- (iv) Shri Bhiva Ram Yadav, Assistant Director (Pricing)

1. Agenda item no. 1 - Confirmation of the Minutes of the 144th Meeting held on 24.03.2026.

1.1 The Authority confirmed the minutes of the meeting without any change.

2. Agenda item no. 2 – Action Taken Report (ATR) on decisions taken by NPPA in its 144th Meeting held on 24.03.2026.

2.1 Noted.

3. Agenda item no. 3 – Status of new drug application.

3.1 Noted.

4. Agenda item no. 4 – New Drug application for price fixation under Paragraph 5 and 15 of DPCO, 2013.

4.1 The Authority deliberated on 43 (Forty-Three) cases of retail price fixation of new drugs as presented in Agenda no. 4(1) to 4(43) falling under the purview of paragraph 2(1)(u) of DPCO, 2013. The Authority approved the retail prices of 42 (Forty-Two) new drugs under paragraph 5 and 15 of DPCO, 2013 as given in **Table 1 below:**

Table No. 1: Retail price fixation of new drugs

Sl. No.	Agenda Item No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
1	4(1)	Aceclofenac, Paracetamol & Serratiopeptidase Tablets	Each film coated tablet contains: Aceclofenac IP 100 mg Paracetamol IP 325 mg Serratiopeptidase IP 15 mg (As enteric coated eq. to enzyme activity 30,000 units)	1 Tablet	M/s Pinnacle Life Science Pvt. Ltd./ M/s Softdeal Pharmaceutical Pvt. Ltd.	10.18
2	4(2)	Acetylcysteine & Taurine Tablets	Each film coated tablet contains: Acetylcysteine USP 150 mg Taurine USP 500 mg	1 Tablet	M/s Talent Healthcare/ M/s Zorvia Healthcare Ltd.	14.72
3	4(3)	Albendazole & Ivermectin Tablets	Each uncoated chewable tablet contains: Albendazole IP 400 mg Ivermectin IP 6 mg	1 Tablet	M/s Theta Pharmaceuticals Ltd./ M/s Aristo Laboratories Pvt. Ltd.	29.60
4	4(4)	Atorvastatin & Ezetimibe Tablets	Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 10mg Ezetimibe IP 10mg	1 Tablet	M/s East African (I) Overseas/ M/s Aristo Pharmaceuticals Pvt. Ltd.	21.36
5	4(5)	Atorvastatin & Ezetimibe Tablets	Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 20mg Ezetimibe IP 10mg	1 Tablet	M/s East African (I) Overseas/ M/s Aristo Pharmaceuticals Pvt. Ltd.	27.50
6	4(6)	Atorvastatin & Ezetimibe Tablets	Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 40mg Ezetimibe IP 10mg	1 Tablet	M/s East African (I) Overseas/ M/s Aristo Pharmaceuticals Pvt. Ltd.	32.46
7	4(7)	Atorvastatin and Clopidogrel Capsules	Each hard gelatin capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 10 mg (as pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg (as pellets)	1 Capsule	M/s Safetab Life Science/ M/s Corona Remedies Ltd.	15.36
8	4(8)	Atorvastatin and Clopidogrel Capsules	Each hard gelatin capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 20 mg (as pellets)	1 Capsule	M/s Safetab Life Science/ M/s Corona Remedies Ltd.	20.96



Sl. No.	Agenda Item No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
			Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg (as pellets)			
9	4(9)	Atorvastatin and Clopidogrel Capsules	Each hard gelatin capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 40 mg (As green coloured spherical pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg (As two brown coloured film coated tablets Each containing 37.5 mg Clopidogrel Tablets IP)	1 Capsule	M/s Windlas Biotech Ltd./ M/s Corona Remedies Ltd.	30.48
10	4(10)	Cefixime & Potassium Clavulanate Tablets	Each film coated tablet contains: Cefixime (as Trihydrate) IP eq. to Anhydrous Cefixime 200 mg Potassium Clavulanate Diluted IP Eq. to Clavulanic Acid 125 mg	1 Tablet	M/s Purobien Lifesciences/ M/s Unison Pharmaceuticals Pvt. Ltd.	25.00
11	4(11)	Cefuroxime Axetil & Potassium Clavulanate Tablets	Each film coated tablet contains: Cefuroxime Axetil IP eq. to Cefuroxime 250 mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 125 mg	1 Tablet	M/s Associated Biopharma Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd.	38.35
12	4(12)	Cefuroxime Axetil & Potassium Clavulanate Tablets	Each film coated tablet contains: Cefuroxime Axetil IP eq. to Cefuroxime 500 mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 125 mg	1 Tablet	M/s Associated Biopharma Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd.	63.94
13	4(13)	Cefuroxime Axetil Tablets	Each film coated tablet contains: Cefuroxime Axetil IP eq. to Anhydrous Cefuroxime 250 mg	1 Tablet	M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s Glensmith Labs Pvt. Ltd.	28.41
14	4(14)	Cefuroxime Axetil Tablets	Each film coated tablet contains: Cefuroxime Axetil IP eq. to Anhydrous Cefuroxime 250 mg	1 Tablet	M/s Theon Pharmaceuticals Ltd./ M/s Aristo Laboratories Pvt. Ltd.	29.42



Sl. No.	Agenda Item No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
15	4(15)	Clopidogrel, Aspirin & Atorvastatin Capsules	Each hard gelatin capsule contains: Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg Aspirin IP 75mg (as Gastro-resistant tablet) Atorvastatin Calcium IP eq. to Atorvastatin 10 mg (as film coated tablet)	1 Capsule	M/s Safetab Life Science/ M/s Corona Remedies Ltd.	6.19
16	4(16)	Clopidogrel, Aspirin & Atorvastatin Capsules	Each hard gelatin capsule contains: Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg Aspirin IP 75 mg (as Gastro-Resistant Tablet) Atorvastatin Calcium IP eq. to Atorvastatin 20 mg (as film coated tablet)	1 Capsule	M/s Safetab Life Science/ M/s Corona Remedies Ltd.	8.80
17	4(17)	Etoricoxib & Paracetamol Tablets	Each film coated tablet contains: Etoricoxib IP 60 mg Paracetamol IP 325 mg	1 Tablet	M/s Aagya Biotech Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd.	10.58
18	4(18)	Ferric Ammonium Citrate, Cyanocobalamin, Folic Acid, Cupric Sulphate & Manganese Sulphate Syrup	Each 15 ml (one tablespoonful) contains: Ferric Ammonium Citrate IP 160mg (eq. to Elemental Iron 32.8 mg) Cyanocobalamin IP 7.5 mcg Folic Acid IP 0.5 mg Cupric Sulphate USP 30 mcg Manganese Sulphate USP 30 mcg	1 ml	M/s Crest Lifesciences Pvt. Ltd./ M/s Troikaa Pharmaceuticals Ltd.	0.88
19	4(19)	Gliclazide & Metformin Hydrochloride Tablets	Each uncoated tablet contains: Gliclazide IP 80 mg Metformin Hydrochloride 500 mg	1 Tablet	M/s Alkem Health Science (A unit of Alkem Laboratories Ltd.)/ M/s Alkem Wellness Ltd.	10.53
20	4(20)	Ivermectin & Albendazole Tablets	Each uncoated chewable tablet contains: Ivermectin IP 6 mg Albendazole IP 400 mg	1 Tablet	M/s Ved Lifesavers (P) Ltd./ M/s Wockhardt Ltd.	29.60

SP

Sl. No.	Agenda Item No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
21	4(21)	Labetalol Hydrochloride Tablets	Each film coated tablet contains: Labetalol Hydrochloride IP 200 mg	1 Tablet	M/s Samarth Life Sciences Pvt. Ltd.	23.17
22	4(22)	L-Carnitine L-Tartrate, Methylcobalamin & Folic Acid Tablets	Each film coated tablet contains: L-Carnitine L-Tartrate eq. to L-Carnitine 500 mg Methylcobalamin IP 1500 mcg Folic Acid IP 1.5 mg	1 Tablet	M/s Windlas Biotech Ltd./ M/s Glensmith Labs Pvt. Ltd.	16.39
23	4(23)	Levosulbutamol & Ipratropium Bromide Respirator Solution	Each 2.5 ml contains: Levosulbutamol Sulphate IP eq. to Levosalbutamol 0.63 mg Ipratropium Bromide IP eq. to Ipratropium (Anhydrous) 500 mcg	1 ml	M/s Axa Parenterals Ltd./ M/s Mankind Pharma Ltd.	6.32
24	4(24)	Lobeglitazone Sulfate & Metformin Hydrochloride (Extended Release) Tablets	Each film coated bilayered tablet contains: Lobeglitazone Sulfate 0.5 mg Metformin Hydrochloride IP 500 mg (As Extended release)	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Zuventus Healthcare Ltd.	10.34
25	4(25)	Lobeglitazone Sulfate & Metformin Hydrochloride (Extended Release) Tablets	Each film coated bilayered tablet contains: Lobeglitazone Sulfate 0.5 mg Metformin Hydrochloride IP 1000 mg (As Extended release)	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Zuventus Healthcare Ltd.	11.99
26	4(26)	Methylprednisolone Tablets	Each uncoated tablet contains: Methylprednisolone IP 8 mg	1 Tablet	M/s Foregen Healthcare Ltd./ M/s Zorvia Healthcare Ltd.	6.00
27	4(27)	Metoprolol Succinate (Extended Release), Chlorthalidone & Telmisartan Tablets	Each film coated tablet contains: Metoprolol Succinate IP 23.75 mg eq. to Metoprolol Tartrate 25 mg (As extended-release) Chlorthalidone IP 12.5 mg Telmisartan IP 40 mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Primus Remedies Pvt. Ltd.	11.99
28	4(28)	Metoprolol Succinate (Extended Release), Chlorthalidone	Each film coated tablet contains: Metoprolol Succinate IP 47.50 mg eq. to Metoprolol Tartrate 50 mg (As extended-	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Primus	14.44

Sl. No.	Agenda Item No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
		& Telmisartan Tablets	release) Chlorthalidone IP 12.5 mg Telmisartan IP 40 mg		Remedies Pvt. Ltd.	
29	4(29)	Olanzapine & Fluoxetine Tablets	Each film coated tablet contains: Olanzapine IP 5 mg Fluoxetine Hydrochloride IP eq. to Fluoxetine 20 mg	1 Tablet	M/s Windlas Biotech Ltd./ M/s Cadila Pharmaceuticals Ltd.	10.64
30	4(30)	Olanzapine & Fluoxetine Tablets	Each film coated tablet contains: Olanzapine IP 10 mg Fluoxetine Hydrochloride IP eq. to Fluoxetine 20 mg	1 Tablet	M/s Windlas Biotech Ltd./ M/s Cadila Pharmaceuticals Ltd.	13.40
31	4(31)	Paracetamol & Mefenamic Acid Suspension	Each 5 ml contains: Paracetamol IP 125 mg Mefenamic Acid IP 50 mg	1 ml	M/s Foregen Healthcare Ltd./ M/s Zorvia Healthcare Ltd.	0.79
32	4(32)	Paracetamol, Caffeine, Diphenhydramine Hydrochloride & Phenylephrine Hydrochloride Tablets	Each uncoated tablet contains: Paracetamol IP 500mg Caffeine (Anhydrous) IP 30mg Diphenhydramine Hydrochloride IP 25mg Phenylephrine Hydrochloride IP 5 mg	1 Tablet	M/s Unispeed Pharmaceuticals Pvt. Ltd./ M/s Smart Laboratories Pvt. Ltd.	4.52
33	4(33)	Relugolix, Estradiol & Norethindrone Acetate Tablets	Each film coated tablet contains: Relugolix 40 mg Estradiol Hemihydrate USP eq. to Estradiol 1 mg Norethindrone Acetate USP 0.5 mg	1 Tablet	M/s Macmillon Pharmaceuticals Pvt. Ltd./ M/s Alembic Pharmaceuticals Ltd.	120.62
34	4(34)	Relugolix, Estradiol & Norethindrone Acetate Tablets	Each tablet contains: Relugolix 40 mg Estradiol Hemihydrate USP eq. to Estradiol 1 mg Norethindrone Acetate USP 0.5 mg	1 Tablet	M/s Macmillon Pharmaceuticals Pvt. Ltd./ M/s Emcure Pharmaceuticals Ltd.	107.22
35	4(35)	Relugolix, Estradiol & Norethindrone Acetate Tablets	Each film coated tablet contains: Relugolix 40 mg Estradiol Hemihydrate USP eq. to Estradiol 1 mg Norethindrone Acetate USP 0.5 mg	1 Tablet	M/s Macmillon Pharmaceuticals Pvt. Ltd./ M/s Jagsonpal Pharmaceuticals Ltd.	107.22
36	4(36)	Relugolix, Estradiol &	Each film coated tablet contains: Relugolix 40 mg	1 Tablet	M/s Macmillon Pharmaceuticals Pvt. Ltd./	107.22

Sl. No.	Agenda Item No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
		Norethindrone Acetate Tablets	Estradiol Hemihydrate USP eq. to Estradiol 1 mg Norethindrone Acetate USP 0.5 mg		M/s Aristo Pharmaceuticals Pvt. Ltd.	
37	4(37)	Relugolix, Estradiol & Norethindrone Acetate Tablets	Each tablet contains: Relugolix 40 mg Estradiol Hemihydrate USP eq. to Estradiol 1 mg Norethindrone Acetate USP 0.5 mg	1 Tablet	M/s Macmillon Pharmaceuticals Pvt. Ltd./ M/s Zydus Healthcare Ltd.	116.00
38	4(38)	Relugolix, Estradiol & Norethindrone Acetate Tablets	Each film coated tablet contains: Relugolix 40 mg Estradiol Hemihydrate IP eq. to Anhydrous Estradiol 1 mg Norethindrone Acetate USP 0.5 mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Intas Pharmaceuticals Ltd.	110.00
39	4(39)	Tacrolimus Prolonged Release Capsules	Each hard gelatin capsule contains: Tacrolimus IP 3 mg	1 Capsule	M/s Zydus Lifesciences Ltd.	Deferred (Note 1)
40	4(40)	Telmisartan, Amlodipine & Hydrochlorothiazide Tablets	Each film coated tablet contains Telmisartan IP 40 mg Amlodipine Besilate IP eq. to Amlodipine 5 mg Hydrochlorothiazide IP 12.5 mg	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Alkem Wellness Ltd.	12.19
41	4(41)	Telmisartan, Chlorthalidone & Metoprolol Succinate (ER) Tablets	Each film coated tablet contains: Telmisartan IP 40 mg Chlorthalidone IP 12.5 mg Metoprolol Succinate IP 47.50 mg eq. to Metoprolol Tartrate 50 mg (As extended-release)	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Alkem Wellness Ltd.	14.44
42	4(42)	Telmisartan, Chlorthalidone & Metoprolol Succinate (ER) Tablets	Each film coated tablet contains: Telmisartan IP 40 mg Chlorthalidone IP 12.5 mg Metoprolol Succinate IP 23.75 mg eq. to Metoprolol Tartrate 25 mg (As extended-release)	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Alkem Wellness Ltd.	11.99
43	4(43)	Vitamin D3 Oral Solution	Each 5 ml contains: Cholecalciferol IP 60000 IU (in Nano Droplet Form)	1 ml	M/s Foregen Healthcare Ltd./ M/s Zorvia Healthcare Ltd.	15.74

Note 1- The Authority noted that a representation dated 31.03.2026 has been received against the Draft Working Sheet. The issues raised therein needs to be examined by the subject experts and as such decided to refer the matter to Multidisciplinary Committee of Experts for further examination.

5. Agenda No. 5: Minutes of 76th meeting of the Multidisciplinary Committee of Experts held on 08.04.2026.

5.1 Noted.

6. Agenda No. 6: Application for extension of separate ceiling prices under Para 11(3) of the DPCO, 2013 for IV fluids in Euro Head/ Euro Head Dual Port with packaging in non-glass with special feature by M/s Silica Healthcare Pvt. Ltd.

6.1 The Authority noted that M/s Silica Healthcare Pvt. Ltd. vide email dated 14.12.2025 applied for separate ceiling prices under Para 11(3) of the DPCO, 2013 for Euro Head/ Euro Head Dual Port bottles with special features for the following IV fluids:

Sr. No.	Name of Product	Pack size	Notification
1	Dextrose Injection IP (5% w/v) - Euro Head	500 ml	1485(E) dated 27.03.2025
2	Dextrose Injection IP (5% w/v) - Euro Head Dual Port	500 ml	
3	Sodium Chloride (0.9% w/v) & Dextrose (5% w/v) Injection IP - Euro Head	500 ml	
4	Sodium Chloride (0.9% w/v) & Dextrose (5% w/v) Injection IP - Euro Head Dual Port	500 ml	
5	Sodium Chloride Injection IP (0.9% w/v) - Euro Head	500 ml	
6	Sodium Chloride Injection IP (0.9% w/v) - Euro Head Dual Port	500 ml	
7	Sodium Chloride Injection IP (0.9% w/v) - Euro Head	100 ml	
8	Sodium Chloride Injection IP (0.9% w/v)- Euro Head Dual Port	100 ml	

6.2 The Authority noted that the matter was deliberated by the MDC in its 75th meeting held on 11.02.2026, and 76th meeting held on 08.04.2026, wherein the company demonstrated its products. The company further requested to extend the present applicable separate ceiling prices as notified vide S.O. 1583(E) dated 25.03.2026. The Committee examined the documents relating to flow rate analysis, certificate of analysis for plastic used in manufacturing of the plastic containers for the applied formulations. The Committee noted that the product bears the features of self-sealability, self-collapsibility and has a dual port to prevent the contamination. Accordingly, the Committee recommended the present applicable separate ceiling price for 8 formulations.

6.3 The Authority deliberated upon the matter and approved the recommendation of the MDC to extend the present applicable separate ceiling price to M/s Silica Healthcare Pvt. Ltd. under the provision of Para 11 (3) of DPCO 2013 as below:

Sr. No.	Name of Product	Pack size	Ceiling price ex. GST	Notification
1	Dextrose Injection IP (5% w/v) - Euro Head	500 ml	84.24 / Pack	1583(E) dated 25.03.2026
2	Dextrose Injection IP (5% w/v) - Euro Head Dual Port	500 ml		
3	Sodium Chloride (0.9% w/v) & Dextrose (5% w/v) Injection IP - Euro Head	500 ml		

Sr. No.	Name of Product	Pack size	Ceiling price ex. GST	Notification
4	Sodium Chloride (0.9% w/v) & Dextrose (5% w/v) Injection IP - Euro Head Dual Port	500 ml		
5	Sodium Chloride Injection IP (0.9% w/v) - Euro Head	500 ml	90.05 / Pack	
6	Sodium Chloride Injection IP (0.9% w/v) - Euro Head Dual Port	500 ml		
7	Sodium Chloride Injection IP (0.9% w/v) - Euro Head	100 ml	43.07 / Pack	
8	Sodium Chloride Injection IP (0.9% w/v)- Euro Head Dual Port	100 ml		

7. **Agenda No. 7: Status of implementation of Review cases**

7.1 Noted.

The meeting ended with a vote of thanks to the Chair and all the participants in the meeting.


 (Sai Ahladini Panda)
 Member Secretary